Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Medisynbio is a biotechnology and nutraceutical company specializing in patented synbiotic formulas designed to modulate the gut microbiome and address chronic inflammatory conditions. The company's products combine probiotics, prebiotics (including Human Milk Oligosaccharides), and potent antioxidants like astaxanthin to remedy dysbiosis and reduce inflammatory biomarkers such as TNF-alpha and calprotectin. Medisynbio's commercial portfolio includes targeted bio-supplements such as Gastrosyn for digestive health, Cardiosyn for cardiovascular support, Renosyn for kidney health, and Glucosyn for blood sugar management. Founded by drug discovery and immunology experts, the company leverages a holistic, science-backed approach to optimize human health from within.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Medisynbio.